Adv Ther (2014) 31:575–576
DOI 10.1007/s12325-014-0118-8

ERRATUM

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

Ulrich Costabel · Elisabeth Bendstrup · Vincent Cottin · Pieter Dewint · Jim J. J. Egan · James Ferguson · Richard Groves · Per M. Hellström · Michael Kreuter · Toby M. Maher · Maria Molina-Molina · Klas Nordlind · Alexandre Sarafidis · Carlo Vancheri

To view enhanced content go to www.advancesintherapy.com
Published online: May 8, 2014

Erratum to: Adv Ther
DOI 10.1007/s12325-014-0112-1

The authors of the above-mentioned paper would like to make the following adjustments to their article.

In Table 1, the value in the *Resolved* row in the column *Diarrhea*, *Placebo* [*n* (%)] currently reads '73 (52)'. This should read '73 (86)'. The correct version of the table is provided below (Table 1). The sentence 'At Week 72, pirfenidone also reduced the proportion of patients with a 50 m or greater decrement in 6-min walk distance (31% relative reduction vs.

The online version of the original article can be found under doi:10.1007/s12325-014-0112-1.

U. Costabel (✉)
Department of Pneumology/Allergology, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany
e-mail: ulrich.costabel@ruhrlandklinik.uk-essen.de

E. Bendstrup
Department of Respiratory Medicine and Allergology, Aarhus University Hospital, Aarhus, Denmark

V. Cottin
Hôpital Louis Pradel, Service de Pneumologie, Centre de Référence National des Maladies Pulmonaires Rares, Université Claude Bernard Lyon 1, UMR754, Lyon, France

P. Dewint
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam
The Netherlands

J. J. J. Egan
Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland

J. Ferguson
Department of Dermatology, Ninewells Hospital, Dundee, UK

R. Groves
Division of Genetics and Molecular Medicine, St. John's Institute of Dermatology, King's College London School of Medicine, London, UK

P. M. Hellström
Department of Medical Sciences, Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden

M. Kreuter
Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Centre Heidelberg, Heidelberg, Germany

T. M. Maher
Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

placebo) and…' in the original article should read 'At Week 72, pirfenidone also reduced the proportion of patients with a 50 m or greater decrement in 6-min walk distance (26% relative reduction vs. placebo) and…'. The sentence 'Overall, five (1.4%) and one (0.3%) pirfenidone patients discontinued therapy due to nausea and vomiting, respectively, and two (0.6%) discontinued due to diarrhea' in the original article should read 'Overall, five (1.4%) and one (0.3%) pirfenidone patients discontinued therapy due to nausea and vomiting, respectively, and two (0.6%) placebo patients discontinued due to diarrhea'.

Table 1 Gastrointestinal adverse events in the CAPACITY studies

	Nausea		Diarrhea		Dyspepsia		Vomiting	
	Pirfenidone 2,403 mg/day ($N = 345$)	Placebo ($N = 347$)	Pirfenidone 2,403 mg/day ($N = 345$)	Placebo ($N = 347$)	Pirfenidone 2,403 mg/day ($N = 345$)	Placebo ($N = 347$)	Pirfenidone 2,403 mg/day ($N = 345$)	Placebo ($N = 347$)
Grade 3 or 4 TEAEs, *n* (%)	6 (1.7)	2 (0.6)	2 (0.6)	0 (0.0)	1 (0.3)	2 (0.6)	1 (0.3)	0 (0.0)
TE SAE, *n* (%)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Deaths, *n*	0	0	0	0	0	0	0	0
Hospitalizations, *n* (%)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discontinuation, *n* (%)	5 (1.4)	0 (0.0)	0 (0.0)	2 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Dose modification, *n* (%)	25 (7.2)	7 (2.0)	18 (5.2)	4 (1.2)	8 (2.3)	0 (0.0)	14 (4.1)	3 (0.9)
Events, *n*	195	77	153	85	77	29	62	17
Median duration, days	46	7	7	5	168	4	2	3
Resolved, *n* (%)	149 (76)	65 (84)	130 (85)	73 (86)	40 (52)	23 (79)	59 (95)	17 (100)

TEAE treatment-emergent adverse event, *TE SAE* treatment-emergent severe adverse event, *Grade 3 TEAE* severe or medically significant but not immediately life-threatening events; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care Activities of Daily Living, *Grade 4 TEAE* life-threatening consequences; urgent intervention indicated. InterMune data on file

M. Molina-Molina
Unidad Funcional de Intersticio Pulmonar, Servicio de Neumología, Hospital Universitario de Bellvitge, IDIBELL, CIBERES, Hospitalet de Llobregat, Barcelona, Spain

K. Nordlind
Dermatology and Venerology Unit, Department of Medicine, Solna, Karolinska University Hospital, Stockholm, Sweden

A. Sarafidis
Department of Gastroenterology, Parc Leopold Hospital (CHIREC), Brussels, Belgium

C. Vancheri
Regional Centre for Rare Lung Disease, University of Catania, Catania, Italy